These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7769277)

  • 1. A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection.
    Pluda JM; Cooley TP; Montaner JS; Shay LE; Reinhalter NE; Warthan SN; Ruedy J; Hirst HM; Vicary CA; Quinn JB
    J Infect Dis; 1995 Jun; 171(6):1438-47. PubMed ID: 7769277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
    Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
    Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
    van Leeuwen R; Katlama C; Kitchen V; Boucher CA; Tubiana R; McBride M; Ingrand D; Weber J; Hill A; McDade H
    J Infect Dis; 1995 May; 171(5):1166-71. PubMed ID: 7751691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
    Lewis LL; Venzon D; Church J; Farley M; Wheeler S; Keller A; Rubin M; Yuen G; Mueller B; Sloas M; Wood L; Balis F; Shearer GM; Brouwers P; Goldsmith J; Pizzo PA
    J Infect Dis; 1996 Jul; 174(1):16-25. PubMed ID: 8655986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
    Kavlick MF; Shirasaka T; Kojima E; Pluda JM; Hui F; Yarchoan R; Mitsuya H
    Antiviral Res; 1995 Oct; 28(2):133-46. PubMed ID: 8585767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.
    Wainberg MA; Salomon H; Gu Z; Montaner JS; Cooley TP; McCaffrey R; Ruedy J; Hirst HM; Cammack N; Cameron J
    AIDS; 1995 Apr; 9(4):351-7. PubMed ID: 7540846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
    Bakshi SS; Britto P; Capparelli E; Mofenson L; Fowler MG; Rasheed S; Schoenfeld D; Zimmer B; Frank Y; Yogev R; Jimenez E; Salgo M; Boone G; Pahwa SG
    J Infect Dis; 1997 May; 175(5):1039-50. PubMed ID: 9129064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
    JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.
    van Leeuwen R; Lange JM; Hussey EK; Donn KH; Hall ST; Harker AJ; Jonker P; Danner SA
    AIDS; 1992 Dec; 6(12):1471-5. PubMed ID: 1283519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group.
    Ingrand D; Weber J; Boucher CA; Loveday C; Robert C; Hill A; Cammack N
    AIDS; 1995 Dec; 9(12):1323-9. PubMed ID: 8605051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent new AIDS drugs underscore promise of combination therapy.
    AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal disposition and drug interaction screening of (-)-2'-deoxy-3'-thiacytidine (3TC) in the isolated perfused rat kidney.
    Sweeney KR; Hsyu PH; Statkevich P; Taft DR
    Pharm Res; 1995 Dec; 12(12):1958-63. PubMed ID: 8786973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time.
    Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS
    Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3TC approval may revive AZT's appeal.
    Vazquez E
    Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
    James JS
    AIDS Treat News; 1995 Dec; (no 237):3. PubMed ID: 11363075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
    Schuurman R; Nijhuis M; van Leeuwen R; Schipper P; de Jong D; Collis P; Danner SA; Mulder J; Loveday C; Christopherson C
    J Infect Dis; 1995 Jun; 171(6):1411-9. PubMed ID: 7539472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glaxo broadens access to 3TC.
    Baker R
    BETA; 1995 Sep; ():5. PubMed ID: 11362896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.